Newsletter

Subscribe and recieve updates on this company.

Text STOCKS to 72727 for mobile alerts

We are excited to present Histogenics Corporation (NASDAQ: HSGX).

Full DD Report for HSGX

You must become a subscriber to view this report.


Recent News from (NASDAQ: HSGX)

Histogenics and FDA to Continue Discussions on NeoCart Phase 3 Clinical Trial Data and Potential Regulatory Pathway
WALTHAM, Mass., Nov. 01, 2018 (GLOBE NEWSWIRE) -- Histogenics Corporation (Histogenics) (Nasdaq: HSGX), a leader in the development of restorative cell therapies that may offer rapid-onset pain relief and restored function, today provided an update on the NeoCart regulatory pathway based on...
Source: GlobeNewswire
Date: November, 01 2018 16:05
Histogenics Corporation to Report Third Quarter 2018 Financial Results on November 8, 2018
WALTHAM, Mass., Oct. 25, 2018 (GLOBE NEWSWIRE) -- Histogenics Corporation (Nasdaq: HSGX), a leader in the development of restorative cell therapies that may offer rapid-onset pain relief and restored function, announced it will report its third quarter 2018 financial results on November 8, ...
Source: GlobeNewswire
Date: October, 25 2018 16:15
Your Daily Pharma Scoop: Novocure's Mesothelioma Success, Sangamo's Mixed Results, China's First Homegrown Onco Med
News in focus: NVCR, SGMO Novocure +9.1% after mesothelioma trial shows survival boost Discussion : Novocure ( NVCR ), a midcap biopharma with about $4bn in market capitlization, has seen a tripling of its valuation this year on the back of a slew of positive news. Just about a year a...
Source: SeekingAlpha
Date: September, 06 2018 16:09
Histogenics (HSGX) NeoCart Phase 3 Clinical Trial Results - Slideshow
The following slide deck was published by Histogenics Corporation in conjunction with this Read more ...
Source: SeekingAlpha
Date: September, 06 2018 14:52
Midday Gainers / Losers (09/05/2018)
Gainers: PRQR +62% . MNKD +33% . SBOT +19% . VCEL +18% . NSU +17% . SYBX +15% . CORV +15% . VRA +15% . MVIS +14% . IGC +13% . More news on: ProQR Therapeutics, MannKind Corporation, Stellar Biotechnologies Inc., Stocks on the move, , Read more ...
Source: SeekingAlpha
Date: September, 05 2018 12:47
Premarket Losers as of 9:05 am (9/5/2018)
HSGX   -75%  on announcing results from Phase 3 trial of NeoCart in patients with knee cartilage damage. More news on: Histogenics Corporation, Sangamo Therapeutics, Inc., The9 Limited, Stocks on the move, , Read more ...
Source: SeekingAlpha
Date: September, 05 2018 09:14
Histogenics down 45% on announcing results from Phase 3 trial of NeoCart in patients with knee cartilage damage
Histogenics Corporation (NASDAQ: HSGX ) announces that its Phase 3 clinical trial of NeoCart did not meet the primary endpoint of a significant improvement in pain and function in a dual threshold responder analysis one year after treatment as compared to microfracture. More news on...
Source: SeekingAlpha
Date: September, 05 2018 06:16

 


Last 5 Days Trading Activity

DateOpen PriceClose PriceHighLowVolume
2018-12-180.57590.530.57590.5012,875,811
2018-12-170.54860.5536360.580.5313,044,575
2018-12-140.520.54920.570.51762,549,571
2018-12-130.520.5196160.54510.49671,512,476
2018-12-120.44240.54040.580.437,263,228

Last 5 Days Short Activity

DateShort VolumeTotal VolumeShort PercentageShort Indicator
2018-12-18470,262859,28054.7274Short
2018-12-17584,872990,68659.0371Short
2018-12-14338,695601,35856.3217Short
2018-12-13221,048386,49357.1933Short
2018-12-121,528,8332,439,39362.6727Short

* Short Mode

Short Analysis provided by Squeeze Report. Get a complete short report on HSGX.


About Histogenics Corporation (NASDAQ: HSGX)

Logo for Histogenics Corporation (NASDAQ: HSGX)

Not available

 

Contact Information

     

     

    Current Share Structure

       



      Daily Technical Chart for (NASDAQ: HSGX)

      Daily Technical Chart for (NASDAQ: HSGX)


      Stay tuned for daily updates and more on (NASDAQ: HSGX)

      It most certainly could but even more important is the recent overwhelming interest in the company. Check out Investors Hub and search on Twitter

      More to come on (NASDAQ: HSGX)

      Do your DD and if you choose, be ready to go!


       

      The Research: All source information contained in this email is from the public sources mentioned below.

       

       
       

      Thank you

      DD Report
      @DDReports

       

       


      Disclaimer: DD Report publishes reports providing information on selected companies. DD Report is not a registered investment advisor or broker-dealer. This report is provided as an information service only, and the statements and opinions in this report should not be construed as an offer or solicitation to buy or sell any security. DD Report accepts no liability for any loss arising from an investors reliance on or use of this report. An investment in HSGX is considered to be highly speculative and should not be considered unless a person can afford a complete loss of investment. DD Report has received no compensation for the publication and circulation of this report. DD Report does not own any shares of HSGX and does not buy, sell, or trade any shares of HSGX. This report contains forward-looking statements, which involve risks, and uncertainties that may cause actual results to differ materially from those set forth in the forward-looking statements. Copyright 2018 by DD Report. All rights reserved. Our Full Disclaimer: https://dd.report/disclaimer/